Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Benzinga Newsdesk 1 day ago
News
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced that Veru had a podium
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced that Veru had a podium presentation at ObesityWeek 2026 in Washington DC. The presentation reviewed the results of the new post hoc physical function subset analysis conducted in patients ≥65 years of age with obesity from the Phase 2b placebo-controlled, randomized, QUALITY clinical study that evaluated enobosarm, a novel SARM, in 168 randomized older patients (≥60 years) with obesity receiving semaglutide for weight loss. The post hoc physical function subset analysis strongly supports the patient population that was selected for the ongoing Phase 2b PLATEAU clinical study.
The title of the podium presentation was "Enobosarm in Patients with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function." Steven Heymsfield, MD; Caroline Apovian MD; Adrian S. Dobs, MD; William Evans, PhD; Domingo Rodriguez, MD; Johannah Sanchez-Adams, PhD; K. Gary Barnette, PhD; Mitchell Steiner, MD; Louis Aronne, MD.
Highlights of the presentation by Dr. Gary Barnette, Chief Scientific Officer Veru, Inc.:
In the Phase 2 QUALITY study for all 164 subjects that completed 8 step stair climb test at baseline, stair climb test was able to detect declines in stair climb power (p <0.001) and slower stair climb time (p=0.002) with age with a 2% loss of stair climb power per year in patients with obesity from age 60 to 84 years of age. This current analysis is consistent with the scientific literature that supports the stair climb test as a valid test that is able to detect declines in physical function in older patients with obesity.
A post hoc subset analysis of physical function in the Phase 2b QUALITY clinical study was conducted comparing enobosarm 3mg + semaglutide versus placebo + semaglutide in 92 subjects ≥65 years of age from baseline to 16 weeks:
Lean mass (DXA): enobosarm 3mg treatment preserved 100% of lean mass at 16 weeks (enobosarm 0.3 kg vs placebo -2.0 kg; p=0.0001).
Physical function (8-step stair climb test): Enobosarm 3mg treatment preserved physical function at 16 weeks.
Stair climb time: Despite significant weight loss, the proportion of patients who climbed the stairs slower was higher in the placebo + semaglutide group compared to the enobosarm 3mg + semaglutide group (42% placebo versus 12% enobosarm; p=0.027)
Stair climb power: the proportion of patients who had a ≥ 10% decline in physical. function was higher in the placebo + semaglutide group compared to the enobosarm 3mg group (42% placebo versus 0% enobosarm; p<0.001).
Conclusions from post hoc subset analysis in older patients (≥65 years of age):
In older patients (≥65 years of age), rapid weight loss with GLP-1 RA treatment was associated with a reduction in physical function by 16 weeks. Patients receiving GLP-1 alone ascended the stairs at a slower rate and had a reduction in stair climb power. Further, 42% of the patients on semaglutide alone had ≥10% loss in stair climb power in 16 weeks which represents 7-10 years of loss expected from aging in this population.
In contrast, enobosarm 3 mg added to GLP-1 RA treatment preserved physical function by 16 weeks. Enobosarm patients ascended the stairs faster and gained stair climb power. No patients (≥65 years of age) had a ≥10% decline in stair climb power in the study.
